NeuroSense Therapeutics Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Form 6 K - Marketscreener.com
| NRSNW Stock | USD 0.25 0.13 34.21% |
Slightly above 65% of NeuroSense Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding NeuroSense Therapeutics Ltd suggests that many traders are alarmed. NeuroSense Therapeutics' investing sentiment can be driven by a variety of factors including economic data, NeuroSense Therapeutics' earnings reports, geopolitical events, and overall market trends.
NeuroSense |
NeuroSense Therapeutics Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Form 6 K Marketscreener.com
Read at news.google.com
 |
NeuroSense Therapeutics Fundamental Analysis
We analyze NeuroSense Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuroSense Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuroSense Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
NeuroSense Therapeutics is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
NeuroSense Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeuroSense Therapeutics stock to make a market-neutral strategy. Peer analysis of NeuroSense Therapeutics could also be used in its relative valuation, which is a method of valuing NeuroSense Therapeutics by comparing valuation metrics with similar companies.
Peers
NeuroSense Therapeutics Related Equities
| GOVXW | GeoVax Labs | 0.00 |
| ||
| NRSN | Neurosense Therapeutics | 7.53 |
|
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.